Androgen resistance is associated with a wide range of quantitative and qualitative defects in the androgen receptor. However, fibroblast cultures from -10% of patients with the clinical, endocrine, and genetic features characteristic of androgen resistance express normal quantities of apparently normal androgen receptor in cultured genital skin fibroblasts (receptorpositive androgen resistance). We have analyzed the androgen receptor gene of one patient (P321) with receptor-positive, complete testicular feminization and detected a single nucleotide substitution at nucleotide 2006 (G --C) within the second "zinc finger" of the DNA-binding domain that results in the conversion of the arginine residue at position 615 into a proline residue. Introduction of this mutation into the androgen receptor cDNA and transfection of the expression plasmid into eukaryotic cells lead to the synthesis of a receptor protein that displays normal binding kinetics but is inactive in functional assays of receptor activity. We conclude that substitution mutations in the DNA-binding domain of the androgen receptor are one cause of "receptor-positive" androgen resistance. (J.
Introduction
Mutations of the androgen receptor cause resistance to the action of testosterone and dihydrotestosterone and result in a spectrum of phenotypic abnormalities in 46,XY individuals ranging from women with the syndrome ofcomplete testicular feminization to men with minor degrees ofundervirilization. A variety of androgen receptor assays have been utilized to define four broad categories of receptor defects: absence of receptor binding, decreased amount of receptor, qualitative abnormality of the receptor, and receptor-positive androgen resistance (1) . This latter designation refers to patients whose fibroblasts demonstrate normal levels ofreceptor and in whom no qualitative abnormalities of the receptor protein have been detected. Whereas the molecular abnormalities that cause decreased amounts of the androgen receptor or impair receptor function
Received for publication 30 October 1990. in those patients with qualitative and quantitative abnormalities of the androgen receptor are believed to involve the androgen receptor gene, the cause ofreceptor-positive androgen resistance is unclear. On one hand, receptor-positive androgen resistance could be due to molecular defects in the receptor that impair some step in receptor function distal to ligand binding, such as the binding of the hormone-receptor complex to the nuclear acceptor site, or it could be due to impairment of an even more distal process in the pathway of androgen action. In the present paper we present detailed studies of the androgen receptor gene ofa patient with complete testicular feminization associated with an apparently normal androgen receptor. The analysis of the sequence of the androgen receptor gene showed the presence ofa single point mutation that converts an adenosine to a guanosine residue at nucleotide 2006 of the androgen receptor cDNA and results in the replacement of arginine 615 with a proline residue. This mutation is located within the second "zinc finger" of the DNA-binding domain, a region believed to be important for the interaction of the androgen receptor protein with androgen-responsive DNA sequences.
Methods
Cell culture. Fibroblasts were grown from genital skin biopsies in DMEM supplemented with 10% FCS and 1% penicillin and streptomycin. The CV-1 cell line was obtained from American Type Culture Collection (Rockville, MD) and grown in DMEM supplemented with 10% FCS and 1% penicillin and streptomycin. DNA was prepared from confluent fibroblast cultures by modification of standard methods (2) .
Androgen receptor gene amplification. Genomic DNA from genital skin fibroblasts ofpatient P321 was amplified as described by the manufacturer using 1 ztg of genomic DNA and 5 U Taq I polymerase. The sequence and the location of the oligonucleotides used for the amplification has been published elsewhere (3) . Amplified bands were cut with Eco RI, subcloned in the sequencing vector MP 18 and sequenced by using the dideoxysequencing method (4) . The number of glycine repeats contained within the glycine homopolymeric segment could not be ascertained unambiguously, and the number reported (see below) represents a minimum estimate (3) . The Fig. 1 After transfection, the cells were incubated with medium containing 2 nM 5a-dihydrotestosterone. The incubation with hormone was continued for a total of 48 h and was changed after 24 h. Each value represents the average of five separate determinations.
single difference compared to the sequence of the normal androgen receptor: change of the arginine residue at amino acid 615 to a proline residue. This arginine is located within the carboxy terminal portion of the second zinc finger and is conserved among a number of steroid hormone receptors (14) . element, and the second finger, rich in basic amino acids, is important for contacting the DNA phosphate backbone and for stabilizing the protein-DNA binding (15) . The region important for specificity has been localized to a group of amino acid residues at the base of the first zinc finger ( 16, 17) . The mutation identified in patient P321 is interesting in several respects. First, it replaces the arginine residue at amino acid 615. Although not absolutely conserved, a basic amino acid is present at this position in all steroid receptors, implying that the charge of the amino acid residue at this position may be important to receptor function. Second, this mutation not only removes a basic amino acid but also introduces into this position a residue that is certain to disrupt higher order structure. In fact, this proline residue substitution is positioned in the center of a segment that has an alpha helical conformation in the DNA-binding domain of the glucocorticoid receptor (18) . Third, the mutation is similar to mutations in patients with the receptor-positive form of complete vitamin D resistance ( 19, 20) . In this regard, it is interesting to note that most mutations identified in the DNA-binding domain of the vitamin D receptor that cause complete hormone resistance are located in the exon encoding the second zinc finger. Whether this is a statistical aberration or has biological significance will await further study.
The alteration of the structure of the androgen receptor predicted for patient P321 would be expected to impair the interaction of the androgen-receptor complex with androgen responsive elements. In agreement with this expectation, the cotransfection of the expression plasmid encoding the mutant androgen receptor CMV321 and the MMTV-CAT reporter plasmid demonstrate that the P321 mutant receptor is severely impaired in its ability to activate the CAT reporter gene. The fact that androgen receptor mRNA levels are normal in fibroblasts from patient P321 suggests that dysfunction ofthe receptor is responsible for the phenotype ofcomplete androgen resistance. These findings also imply that a mutant androgen receptor that exhibits 2% of normal activity and is not modified by other factors (such as an alteration in the level of androgen receptor mRNA) is unable to support significant male phenotypic development.
The definition of the mutation in the androgen receptor gene of patient P321 raises several questions regarding the genetic defects within the spectrum of patients with receptorpositive androgen resistance. Whereas the receptor-negative form is characterized by premature truncation of the receptor protein (2, 3, 21) 
